Table 2 Univariate analysis of the association between clinicopathological characteristics and the BRAF V600E mutation
From: Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma
Variables | BRAFV600Emutation | P-value | |
|---|---|---|---|
Positive (n = 241) | Negative (n = 86) | ||
Age, years, | |||
mean ± SD | 47.63 ± 11.26 | 48.23 ± 10.41 | 0.665 |
≥45 | 85 (35.3%) | 32 (37.2%) | 0.747 |
<45 | 156 (64.7%) | 54 (62.8%) | |
Sex, | |||
male | 39 (16.2%) | 20 (23.3%) | 0.143 |
female | 202 (83.8%) | 66 (76.7%) | |
Tumour size, cm, | |||
mean ± SD, | 1.09 ± 0.72 | 0.89 ± 0.75 | 0.040 |
≤1 cm | 147 (61%) | 66 (76.7%) | 0.009 |
>1 cm | 94 (39%) | 20 (23.3%) | |
Extrathyroidal extension, | |||
yes | 152 (63.1%) | 40 (46.5%) | 0.007 |
no | 89 (36.9%) | 46 (53.5%) | |
Lymph node metastasis, | |||
yes | 110 (47.6%) | 37 (43.5%) | 0.518 |
no | 121 (52.4%) | 48 (56.5%) | |
Central node metastasis, | |||
yes | 110 (47.6%) | 35 (41.2%) | 0.308 |
no | 121 (52.4%) | 50 (58.8%) | |
Lateral node metastasis, | |||
yes | 19 (8.2%) | 9 (10.6%) | 0.512 |
no | 212 (91.8%) | 76 (89.4%) | |
TNM stage, | |||
I | 96 (41.6%) | 41 (48.2%) | 0.138 |
II | 33 (14.3%) | 7 (8.2%) | |
III | 91 (37.7%) | 30 (34.8%) | |
IVA | 11 (6.4%) | 7 (8.8%) | |
Multifocality, | |||
yes | 59 (24.5%) | 23 (26.7%) | 0.678 |
no | 182 (75.5%) | 63 (73.3%) | |
Histology, | |||
classic type | 233 (96.7%) | 78 (90.7%) | 0.027 |
follicular variant | 8 (3.3%) | 8 (3.3%) | |
Concurrent Hashimoto’s thyroiditis, | |||
yes | 35 (14.5%) | 21 (24.4%) | 0.037 |
no | 206 (85.5%) | 65 (75.6%) | |